Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Prepaid Assets: 2019-2024

Historic Prepaid Assets for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $10.1 million.

  • 4D Molecular Therapeutics' Prepaid Assets fell 17.50% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 17.50%. This contributed to the annual value of $10.1 million for FY2024, which is 20.33% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Prepaid Assets of $10.1 million as of FY2024, which was up 20.33% from $8.4 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Prepaid Assets registered a high of $10.1 million during FY2024, and its lowest value of $4.4 million during FY2020.
  • In the last 3 years, 4D Molecular Therapeutics' Prepaid Assets had a median value of $8.4 million in 2023 and averaged $8.5 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first soared by 136.63% in 2020, then fell by 17.73% in 2022.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Prepaid Assets stood at $4.4 million in 2020, then spiked by 90.28% to $8.5 million in 2021, then declined by 17.73% to $7.0 million in 2022, then rose by 20.11% to $8.4 million in 2023, then increased by 20.33% to $10.1 million in 2024.